Organ-on-a-chip was not one invention but a sixty-year argument: that animals deserve better, that humans deserve better data, and that a living micro-environment beats a plastic dish. These are the names and the years.
After the sulfanilamide elixir disaster kills over a hundred Americans, the US Food, Drug, and Cosmetic Act requires toxicity testing before marketing — and animal testing becomes the default gate every drug must pass for the next 84 years.
Zoologist William Russell and microbiologist Rex Burch publish The Principles of Humane Experimental Technique, defining Replacement, Reduction and Refinement — the ethical framework that every alternative-method programme, organ-chips included, still answers to.
Russell W.M.S., Burch R.L., Methuen, London (1959)
George Whitesides' laboratory at Harvard popularises soft lithography in PDMS — casting hair-width channels in a transparent, gas-permeable silicone. Suddenly any laboratory can fabricate microscale plumbing for cells, and the hardware side of organ-on-a-chip exists.
Harvard founds the Wyss Institute for Biologically Inspired Engineering with Hansjörg Wyss's $125 million gift, with Donald Ingber as founding director. The same year, CN Bio Innovations spins out of the University of Oxford to commercialise microphysiological systems — the company later known for its PhysioMimix multi-organ platform.
Dongeun Huh, working in Ingber's Wyss Institute group, publishes the landmark lung-on-a-chip in Science: human alveolar and capillary cells on opposite sides of a porous membrane, air above, flow below, and lateral suction that makes the tissue breathe. The chip reproduces organ-level responses — including inflammatory reaction to bacteria and nanoparticles — that dishes never could.
Huh D., Matthews B.D., Mammoto A., Montoya-Zavala M., Hsin H.Y., Ingber D.E., Science 328, 1662 (2010) — doi:10.1126/science.1188302
Emulate, Inc. is founded by Ingber and Geraldine Hamilton to commercialise the Wyss organ-chip platform — bringing liver, lung, gut and brain chips to pharmaceutical customers, and later sending tissue chips to the International Space Station with Space Tango.
In Advanced Science, Ingber publishes the editorial "Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies?" — turning the chip from an interesting tool into a challenge to the animal-first culture of peer review.
Ingber D.E., Advanced Science 7, 2002030 (2020) — doi:10.1002/advs.202002030
Duxin Sun and colleagues quantify the pipeline's failure: around 90% of drug candidates entering clinical trials do not reach approval, with lack of clinical efficacy and unmanageable toxicity leading the causes — failures animal models did not predict. In December, the FDA Modernization Act 2.0 (S.5002, 117th Congress) is signed into law, removing the blanket requirement for animal testing before human trials and allowing alternatives — organ-chips among them — to support drug applications.
Sun D. et al., Acta Pharmaceutica Sinica B 12, 3049 (2022) — doi:10.1016/j.apsb.2022.02.002 · FDA Modernization Act 2.0, S.5002 (govinfo)
In April 2025 the FDA announces a plan to phase out the animal-testing requirement for monoclonal antibodies and other drugs — explicitly naming organ-on-a-chip systems among the human-relevant methods it wants to see instead. The 1938 door, cracked open in 2022, is now being walked through.
FDA press announcement, April 2025 · Organ-on-a-chip overview
Every platform above models organs for general drug questions. None was designed around peptides — molecules that live and die by minutes of flow, enzyme and receptor — or around stem cells, living medicines that expand and differentiate while you watch. PepStemChip, invented at Panacea Bio Chem by Bogdan Dicoias, is the organ-chip built for those two classes. The gap it fills is public; the blueprint stays Panacea intellectual property until peer review.
In-house platform · design disclosure follows peer review